問卷

TPIDB > Search Result

Search Result

篩選

List

6Cases

2020-10-26 - 2029-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting6Sites

Recruiting1Sites

2025-10-01 - 2029-06-30

Phase III

Active
A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) after Imatinib Therapy (StrateGIST 3)
  • Condition/Disease

    Gastrointestinal Neoplasms

  • Test Drug

    IDRX-42 (GSK6042981) Sunitinib

Participate Sites
6Sites

Recruiting6Sites

2023-08-01 - 2027-04-01

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2022-07-01 - 2028-12-31

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2025-09-18 - 2028-09-28

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-08-01 - 2027-04-01

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites